Navigation Links
Mission Pharmacal Celebrates Historic Milestone
Date:2/2/2009

Pioneer in Women's Health Marks 64 Years of Innovation and Growth

SAN ANTONIO, Feb. 2 /PRNewswire/ -- Mission Pharmacal Company this year celebrates 64 years of excellence in manufacturing and distributing pharmaceutical products primarily for women's health. For more than six decades, Mission Pharmacal has enhanced the quality of consumers' lives through innovative, science-based, quality pharmaceutical products, vitamins and supplements.

Founded in 1945 by H.N. Walsdorf, a pharmacist, the Texas-based company was built on the philosophy that most existing pharmaceutical formulations had the potential to be more effective and better tolerated. Three generations later, Neill B. Walsdorf, Jr. carries on the traditions of quality and value established by his grandfather and continued by his father.

"We are honored to celebrate 64 years in the pharmaceutical industry," said Neill Walsdorf, Jr., president of Mission Pharmacal. "We recognize this achievement and will continue my grandfather's mission to provide breakthrough products and the level of quality that has been associated with the Mission name. In addition to our expertise in current therapeutic areas, we will look to developments in new areas of osteoporosis, urolithiasis and cardiovascular disease."

The company has a broad portfolio of over-the-counter and prescription products that enhance prenatal nutrition, treat parasitic and bacterial infections, prevent kidney stone recurrence and help relieve arthritis and muscle pain. Major brands include the CitraNatal(R) family of prescription prenatal vitamins, designed to support pregnant women's comfort with calcium citrate and other well-tolerated ingredients while optimizing nutrition for their babies' growth and development; Ferralet(R) 90, for iron deficiency anemia, that transforms prescription oral iron therapy into a gentle experience with carbonyl iron; Tindamax(R) (tinidazole), the only oral antimicrobial approved for the treatment of both trichomoniasis and bacterial vaginosis (as well as many other bacterial infections) and Urocit-K(R), a formulation of potassium citrate used to treat nephrolithiasis in people with kidney stones that is the standard treatment in its category.

About Mission Pharmacal Company

Mission Pharmacal is a privately held pharmaceutical company based in San Antonio, Texas. For more than 60 years, Mission has been committed to meeting the unique needs of women throughout all stages of life, identifying unmet health needs in the marketplace, and developing innovative prescription and over-the-counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical and nutritional products. For more information on Mission, visit www.missionpharmacal.com.


'/>"/>
SOURCE Mission Pharmacal Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
2. Light Sciences Oncology Elects Former FDA Commissioner Frank Young, M.D., Ph.D., to Board of Directors
3. Sierra Tucson Achieves Hospital Accreditation, Now Holds Dual Accreditation by the Joint Commission
4. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
5. Fairview Baptist Home Selects PatientPlacement.com to Automate Referrals and Increase Patient and Resident Admissions
6. EliteMeetings.com Announces Commission-Free Policy Comprehensive Search and RFP Engine Now Provides Net Rates for Groups
7. In Time, Cream Might Prevent Herpes Transmission
8. Pennsylvania Insurance Commissioner Welcomes U.S. House Vote to Reauthorize Childrens Health Care
9. One Mans Determined Journey to Remission and a Renewed Sense of Faith
10. Particulate Emission from Natural Gas Burning Home Appliances Is Assessed in Environmental Engineering Science Journal
11. Kansas Insurance Commissioner, Sandy Praeger, to Appear this Saturday on Cary Hall's Health Insurance Advocate Radio Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... New SUPRO® XT55 Isolated ... beverages by helping beverage manufacturers more effectively manage protein costs. “Soy protein has ... as well as more stable pricing over time. Now it’s even more relevant ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... HR decision-makers are preparing for how his administration could impact the employee benefits ... into what changes are most likely to make it through Congress. His discussion ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who ... achieves results in a fraction of the time as traditional braces – Wilckodontics®. ... Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... Minneapolis MN (PRWEB) , ... April 25, 2017 , ... ... patients and recreational users to dispensaries and head shops –can’t help but be heartened ... loathing for the tell-tale cannabis odor aptly described as “skunk smell.” At last ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology: